Indian biotech company Enzene Biosciences Ltd. will open its state-of-the-art biopharmaceutical manufacturing plant in New Jersey,  Choose New Jersey, a nonprofit economic development organization announced.

Welcoming the expansion, NJ’s Governor Phil Murphy said, “I am proud to welcome Enzene Biosciences and their expanding global presence to New Jersey’s flourishing life sciences industry.”

“New Jersey’s favourable business environment, skilled workforce, strategic location, supportive ecosystem for growth, and deep cultural ties are why Indian companies thrive in our state. Enzene Biosciences’ state-of-the-art manufacturing facility will bring hundreds of jobs and generate $50 million in economic investments in our state, further solidifying New Jersey’s position as an innovation economy leader,” he added.

As part of the NJ expansion plans, the company will hire 50 employees to manage the local facility. Its local manufacturing capabilities will provide biopharmaceutical companies in North America with streamlined supply chains, fast turnaround times, enhanced communication, and greater control over the manufacturing process, a release noted.

CEO of Enzene Biosciences, Dr Himanshu Gadgil said, “We are excited to provide them with access to our cutting-edge continuous manufacturing platform, which enables streamlined and efficient production processes. New Jersey’s highly skilled workforce, state-of-the-art infrastructure, and renowned academic institutions make it an ideal location for Enzene, ensuring that we can deliver exceptional services and support to our clients in the U.S.”

Pune-based Enzene Biosciences aims to harness disruptive innovation and enhance global healthcare. The technology driven firm provides its services to healthcare companies and partners with them in their drug development and manufacturing processes